What's new?
27/09/2017

Paris, France – September 27th, 2017 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Henrijette Richter as Managing Partner. She joins Antoine Papiernik, Denis Lucquin, Graziano Seghezzi and Monique Saulnier in the company’s Managing Partnership. With a 14 years’ experience in venture capital, Henrijette brings her extensive industry experience and strong international network to Sofinnova Partners’ leadership.

Henrijette joined Sofinnova Partners in October 2014, after seven years at Novo Holdings A/S (the holding company in the Novo Group) where she co-founded Novo Seeds. Prior to that, she worked at Sunstone Capital and was part of the founding team when the fund spun out of The Danish Growth Foundation. Henrijette is a scientist by training, she holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen, and did her postdoctoral fellowship at MIT Center for Cancer Research, Cambridge, MA.

Since 2014, Henrijette has lead key investments such as in Asceneuron, a biotech company specialized in neurodegenerative diseases headquartered in Switzerland where she also serves on the Board of Directors. Henrijette also seeded and invested in Delinia, a US-based company specialized in the treatment of auto-immune disorders that was sold to Celgene Corporation in January 2017 for a total value of up to $775 M.

Henrijette Richter says: « I am honored by this new role and excited to take a more active role in Sofinnova Partners’ growth strategy to reinforce its global leadership in Life Sciences. I have the foremost respect for the team, its values, the culture of diversity, and the entrepreneur-oriented spirit it has been fostering worldwide for more than forty years ».

Antoine Papiernik, Chairman of Sofinnova Partners, adds: « Henrijette stands out for her investment track record and has demonstrated impressive team leading skills. She is a great addition to our team, and we are extremely pleased to welcome her to the Managing Partnership as Sofinnova Partners is entering a new phase of its development ».
Press contact for SOFINNOVA PARTNERS
Anne REIN
Tel: +33 6 03 35 92 05
@: anne.rein@strategiesimage.com

20/10/2017

Avantium N.V., (Euronext Amsterdam and Brussels: AVTX) (“Avantium” or “the Company”) a leading chemical technology company and forerunner in renewable chemistry, announces that today it has published its convocation of the Extraordinary General Meeting of shareholders (EGM) to be held at Avantium’s headquarters, Zekeringstraat 29, Amsterdam, The Netherlands on 30 November 2017 at 10.00 am CET. On the agenda is the appointment of Mr. Kees Verhaar as a new member to Avantium’s Supervisory Board.

Avantium’s Supervisory Board has nominated Kees Verhaar, who will join the Supervisory Board for a term of four years, subject to approval by shareholders at the EGM. He will succeed Mr. Jan van der Eijk, who had temporarily resumed his role as Chairman of the Supervisory Board of Avantium. Mr. Jan van der Eijk will resign with effect as of immediately after the EGM of 30 November 2017. He will continue in his role as Chairman of the Supervisory Board of Synvina, the Joint Venture of Avantium and BASF.

Once approved by the shareholders as a Supervisory Board member, Kees Verhaar will be appointed as Chairman of the Supervisory Board. His appointment will be effective immediately after the EGM of 30 November 2017.

Kees Verhaar’s experience as CEO of Arizona Chemicals, the world leading wood-based chemicals company and his 30-year track record in the chemical industry, which includes extensive collaboration with sophisticated financial investors are very valuable to support Avantium in building a winning renewable chemistry company. Kees Verhaar is currently chairman of the advisory board of three business units of Ten Cate, an international advanced materials company.

The convocation, agenda and explanatory notes for the EGM together with the resume of Mr. Kees Verhaar are published on the Company’s corporate website.
This is a public announcement by Avantium N.V. pursuant to section 17 paragraph 1 of the European Market Abuse Regulation (596/2014).
About Avantium
Avantium is a leading chemical technology company and a forerunner in renewable chemistry. Together with its partners around the world, Avantium develops efficient processes and sustainable products made from biobased materials. Avantium offers a breeding ground for revolutionary renewable chemistry solutions from invention to commercially viable production processes.
One of Avantium’s success stories is YXY technology, with which it created PEF: a completely new, high-quality plastic made from plant-based industrial sugars. Since October 2016 all YXY activities have been transferred to Synvina, the joint venture of Avantium and BASF.

Avantium is also working on a host of other groundbreaking projects such as the Zambezi process; a biorefinery technology to produce sugars for the production of chemicals and fuels from non-food materials. The proprietary process is highly feedstock-flexible allowing use of forestry residues (e.g. woodchips), corn stover, bagasse and produces a high purity 2G glucose product and lignin for energy and other applications. Avantium also provides advanced catalysis research services and systems to the leading chemical and petrochemical companies.

Avantium shares are listed on Euronext Amsterdam and Euronext Brussels (symbol: AVTX), its offices and headquarters are based in Amsterdam, the Netherlands. Over 120 highly skilled colleagues representing 20 nationalities, Avantium fosters a dynamic and enthusiastic workplace that is constantly seeking new ways to improve and expand the impact of advanced catalytic research & technology.
MEDIA CONTACT
For more information:
Dominique Levant, Marketing & Communications Officer
T: +31 20 586 01 32 – E: dominique.levant@avantium.com
or visit our website www.avantium.com.

19/10/2017

French regulatory Authority, ANSM, approves PRIMA’s feasibility study for advanced dry-AMD
Paris, France. October 19, 2017 – 7.00 AM CET – Pixium Vision (FR0011950641 – PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, today announces that its next-generation miniaturized wireless sub-retinal implant, PRIMA, to restore vision in patients affected by retinal dystrophies, received authorization from the French regulatory agency, Agence Nationale de Sécurité du Médicament et des Produits de santé (ANSM), to start a feasibility clinical study in patients with advanced dry age-related macular degeneration (dry-AMD).
Khalid Ishaque, Chief Executive Officer of Pixium Vision, commented: “The approval of the clinical study is a significant advance for the PRIMA system, our next generation wireless sub-retinal implant system, as well as for Pixium Vision. Conceived initially by the researchers at Stanford University, and successfully developed through to clinical stage by our team at Pixium Vision in close collaboration with numerous physicians and scientists, PRIMA enters an exciting phase of its development, with a first patient expected to be implanted before year end. With ageing population dynamics, advanced dry-AMD is a leading cause of irreversible vision loss1 with currently estimated over 4 million people without approved treatment option making it a significant unmet medical need.”
The clinical study entitled “Feasibility Study of Compensation for blindness with the PRIMA system in patients with dry age related macular degeneration”, is designed to evaluate the tolerance of PRIMA and to demonstrate the evoked central visual perception among patients who have lost their sight due to atrophic advanced dry-AMD. The study is planned to recruit 5 patients with interim evaluation at 6-month follow-up and longer term follow-up to 36 months. The study will be conducted at Fondation Ophtalmologique Rothschild and Hôpital des Quinze-Vingt in Paris with Dr. Yannick Le Mer, vitreoretinal surgeon and ophthalmologist, as principal investigator.
In parallel, Pixium Vision actively pursues its constructive discussions with the US Food and Drug Administration (FDA), in order to also prepare the feasibility study with PRIMA in the US.
Contacts
Pixium Vision
Didier Laurens, CFO
investors@pixium-vision.com
+33 1 76 21 47 68
@PixiumVision

Media Relations
France: Newcap Media
Annie-Florence Loyer – afloyer@newcap.fr
+33 1 44 71 00 12 / +33 6 88 20 35 59
Léa Jacquin – ljacquin@newcap.fr
+33 1 44 71 94 94
Media Relations International: Image Box PR
Neil Hunter
neil@imageboxpr.co.uk
Tel +44 (0)20 8943 4685

ABOUT PRIMA
PRIMA is a miniaturized new generation implant totally wireless. The PRIMA implant is a micro photovoltaic chip of 2 millimeters and 30 microns thick, PRIMA is equipped with 378 electrodes. Implanted under the retina via a less invasive surgical procedure, implant converts pulsed near infra-red invisible light signal received from the external glasses with an integrated mini-camera into electrical signals transmitted to the brain via the optic nerve. PRIMA is designed to treat retinal dystrophies, particularly aiming to treat advanced atrophic dry-AMD, the most prevalent form of Age-related Macular Degeneration, thanks to miniaturization and aimed to preserve patient’s residual peripheral vision. Prima is also intended to be evaluated at a later stage for treatment of vision loss from Retinitis Pigmentosa.

ABOUT PIXIUM VISION
Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention as well as a rehabilitation period. Following the CE mark for its first bionic retinal implant systems, IRIS®II, Pixium Vision has been authorized to start clinical study in Human for PRIMA, a sub-retinal miniaturized wireless implant system. Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, and Moorfields Eye Hospital in London. The company is EN ISO 13485 certified. Pixium Vision is qualified “Entreprise Innovante” par Bpifrance
For more information, please visit: www.pixium-vision.com;
And follow us on: @PixiumVision; www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision

Disclaimer:
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 “Risk Factors” of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF – AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).
IRIS® is a trademark of Pixium-Vision SA
Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.
Pixium Vision is included in the Euronext CAC All Shares index
Euronext ticker: PIX – ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

18/10/2017

Vienna, Austria, 18 October 2017 – Hookipa Biotech AG (“Hookipa”), a company pioneering an innovative class of immunotherapies for oncology and infectious diseases, today announced the appointment of Dr. Jan van de Winkel as Chairman of its Board of Directors.
Dr. Jan van de Winkel is currently President and Chief Executive Officer of Genmab A/S. He is widely recognized as one of the most successful biotech entrepreneurs in the world, with a blend of outstanding scientific and managerial expertise. He has built Genmab from ’bench to bedside’ with commercial stage immunotherapy products.
“We are proud to have attracted Jan to join our board of directors as Chairman,” said Hookipa´s CEO, Mr. Jörn Aldag. “As Hookipa grows and progresses to become an integrated biotech company with multiple clinical programs in infectious diseases and immune-oncology, Jan´s experience of building companies and his scientific insight will prove invaluable”.
As co-founder of Genmab Dr. van de Winkel served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President and CEO in 2010. He has over 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to co-founding Genmab. He is the author of over 300 scientific publications and has been responsible for over 70 patents and pending patent applications. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University and received M.S. and Ph.D. degrees from the University of Nijmegen in the Netherlands.
Commenting on his appointment Dr. van de Winkel said “I am honored to take on the role of Chairman at this exciting time in the life of this very promising company. The powerful stimulation of the natural immune mechanisms in patients is one of the most promising approaches being taken in infectious diseases and cancer – both prophylactically and therapeutically. I believe that Hookipa’s Vaxwave® and TheraT® technologies are among the best in the field and I am looking forward to building the company together with its management team and other board members who have done this very successfully before”.
Hookipa is anticipating the delivery of two major milestones over the next two years. Following the successful completion of a Phase 1 trial for a vaccine against cytomegalovirus (CMV) based on Hookipa’s proprietary Vaxwave® platform, a Phase 2 proof-of-concept study will be initiated in solid organ transplant recipients. In addition, based on unprecedented levels of specific T cells generated in in-vivo studies, the company will conduct a Phase 1 safety and efficacy trial for a TheraT® immunotherapy in Human Papilloma Virus (HPV)-related head and neck cancers with the goal of establishing safety and early efficacy signals.

About Hookipa Biotech
Hookipa Biotech is developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms. By early July 2017, Hookipa has raised EUR 15 million in non-dilutive funds and EUR 37 million equity investment from internationally renowned venture capital investors including Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.
Additional information on Hookipa is available at www.hookipabiotech.com.

About Vaxwave®
Hookipa´s Vaxwave® technology presents a completely new replication-defective viral vector platform designed to overcome the limitations of current technologies. Vaxwave® is based on lymphocytic choriomeningitis virus (LCMV). In this vector the gene encoding the LCMV envelope protein, normally responsible for virus entry into target cells, has been deleted and replaced with a target gene of interest. The resulting vectors infect target cells and stimulate very potent and long-lasting immune responses, however they can no longer replicate and are therefore non-pathogenic and inherently safe.

About TheraT®
Hookipa’s TheraT® platform is based on an attenuated replicating virus and is capable of eliciting the most potent T cell responses – a crucial step in treating patients with aggressive cancers. Significant pre-clinical data demonstrates that TheraT® is a powerful modality capable of turning “cold tumors hot” which should result in an additional layer of efficacy in the fight against solid tumors. Specifically, TheraT® has proven to be safe in animals as well as capable of eliciting uniquely potent antigen-specific CD8+ cytotoxic T cell responses and strong tumor control in mice. The first clinical trial with HB-201 targeting human papilloma virus-induced head and neck cancer is currently being prepared. This immuno-oncology technology is further being leveraged to target tumor self-antigens or shared neoantigens.
Issued for and on behalf of Hookipa Biotech AG by Instinctif Partners. For further information please contact:

At the Company
Marine Popoff
Communications Analyst
Hookipa Biotech AG
Mpopoff@Hookipabiotech.com
Media enquiries
Sue Charles/ Ashley Tapp
Instinctif Partners
hookipa@instinctif.com
+44 (0)20 7866 7905

11/10/2017

Funding to be Used to Expand Commercialization, Advance Clinical Development of Company’s Proprietary Technology Portfolio

Fremont, Calif. — October 9, 2017 — Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today reported $35 million in new financing, an extension of the company’s previously announced $45 million Series C financing. New investor Fidelity Management & Research Company participated, along with certain funds and accounts advised by T. Rowe Price Associates, Inc., a returning investor.

Proceeds from the financing will be used to expand commercialization and advance clinical development of the company’s Peripheral and Coronary Lithoplasty® Systems in the United States and Europe and to advance development of a program evaluating the technology as a potential treatment for aortic valve stenosis.

“We feel extremely fortunate to have received this investment particularly coming from these two funds,” said Doug Godshall, president and CEO of Shockwave Medical. “This infusion enables us to move multiple preclinical, clinical and commercial initiatives forward with greater certainty. Specifically, we will be better equipped to accelerate our commercialization efforts, prepare for the launch of our below-the-knee device globally and our coronary platform outside the United States next year, as well as to commence a chronic human feasibility study of our transcatheter aortic valve lithotripsy system in the first half of the year.”

The Peripheral Lithoplasty System is an innovative therapy designed to treat calcified leg artery blockages with lithotripsy, sonic pressure waves historically used to treat patients with kidney stones. The technology is now commercially available in both the United States and Europe for the treatment of calcified plaque in peripheral arteries. In addition, the Coronary Lithoplasty System received CE mark earlier this year.

A First-In-Human study of transcatheter aortic valve lithotripsy was presented at the PCR London Valves meeting last month. The study demonstrated early feasibility of a new, nonimplant treatment for patients with aortic stenosis. Further studies and a transfemoral design are under development.

About Shockwave Medical’s Lithoplasty® System
Shockwave Medical’s Lithoplasty System integrates the calcium-disrupting power of sonic pressure waves, known as lithotripsy, with angioplasty balloon catheter devices. Each Lithoplasty catheter incorporates multiple lithotripsy emitters activated with the touch of a button after the integrated balloon is inflated. Once activated, these emitters produce therapeutic sonic pressure waves that are inherently tissue-selective, passing through the balloon and soft vascular tissue, preferentially disrupting the calcified plaque inside the vessel wall by creating a series of micro-fractures. When the calcium has been modified, the vessel can be dilated using low pressures, thereby enabling even historically challenging calcified lesions to be treated effectively with minimal injury to the vessel.

The Peripheral Lithoplasty System is commercially available in both the United States and urope and is intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified
lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infrapopliteal, and renal arteries. Not for use in the coronary or cerebral vasculature.
In the European Union, the Shockwave Medical Coronary Rx Lithoplasty System is indicated for lithotripsy enhanced, low-pressure balloon dilatation of calcified, stenotic de novo coronary arteries prior to stenting.

The Shockwave Medical Coronary Lithoplasty System and the Shockwave Medical Transcatheter Aortic Valve Lithotripsy System are investigational devices in the United States and are not available for sale.

To view an animation of the Lithoplasty System visit http://shockwavemedical.com.

About Shockwave Medical
Shockwave Medical, based in Fremont, Calif., is working to reshape interventional therapy with Lithoplasty® Technology for the treatment of calcified peripheral vascular, coronary vascular and heart valve disease. For more information, visit www.shockwavemedical.com.

03/10/2017

New preclinical data in Cancer Immunology Research demonstrate that increasing tumorinfiltrating T cells through inhibition of CXCL12 by NOX-A12 synergizes with PD-1 checkpoint inhibition

Berlin, Germany, October 03, 2017 – NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the publication of novel preclinical data for NOXXON’s lead cancer compound, NOX-A12 (olaptesed pegol). The results highlighted the effects of NOX-A12 in vitro and in an animal model, emphasizing NOX-A12’s ability to enhance the infiltration of T and NK immune cells into tumor tissue thereby synergizing with and overcoming resistance to PD-1 checkpoint inhibition with the goal of enabling the destruction of cancer. Building on extensive clinical experience and safety data, the lead program NOX-A12 will deliver top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018. “Immune checkpoint inhibitors promote T cell-mediated killing of cancer cells and induce striking responses. However, as only a subset of patients benefits from such treatment, nov l strategies to enhance the effect are needed. Although preclinical, we believe that the results of this study further validate the potential of NOX-A12 as a combination therapy to improve outcomes in multiple oncology indications,” said Aram Mangasarian, CEO of NOXXON. “The goal of our current clinical trial is to reproduce these results and to deliver a meaningful therapeutic impact in colorectal and pancreatic cancer patients.”

The pre-clinical study titled “Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade” aimed to evaluate the potential of NOX-A12 as a combination therapy approach to improve checkpoint inhibition therapies. In particular, the study investigated whether NOX-A12-based inhibition of the chemokine CXCL12, a key factor in TMEdriven immune suppression, would increase lymphocyte infiltration into the tumor and thus enable effective killing of cancer cells in combination with checkpoint inhibitors. By employing threedimensional cell culture models that mimic a solid tumor with a CXCL12-abundant TME, it was demonstrated that NOX-A12 enhanced the infiltration of T and NK cells in a dose-dependent manner.
NOX-A12 and PD-1 checkpoint inhibition synergistically enhanced T cell activation in the model indicating that both agents complement each other. The findings were subsequently validated in vivo in a murine model of colorectal cancer where the addition of NOX-A12 significantly improved antiPD-1 therapy. Taken together, the results demonstrate that CXCL12 inhibition can break the immuneprivilege of the TME by paving the way for immune effector cells into the tumor and that NOX-A12 could be an important therapeutic approach to broadening the applicability of checkpoint inhibitors in cancer patients.

The results, published in the current issue of Cancer Immunology Research can be accessed through the current online version of the journal and the following link:
http://cancerimmunolres.aacrjournals.org/cgi/content/abstract/2326-6066.CIR-16-0303
For more information, please contact:

NOXXON Pharma N.V.
Aram Mangasarian, Ph.D., Chief Executive Officer
Tel. +49 (0) 30 726 247 0
amangasarian@noxxon.com

MC Services AG
Raimund Gabriel, Managing Partner
Tel. +49 (0) 89 210228 0
noxxon@mc-services.eu

MacDougall Biomedical
Gretchen Schweitzer or Stephanie May
Tel. +49 (0) 89 2424 3494 or +49 (0) 172 861 8540
gschweitzer@macbiocom.com

NewCap
Florent Alba
Tel. +33 (0) 1 44 71 98 55
falba@newcap.fr

About NOXXON
NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing hemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program
NOX-A12 will deliver top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018. Further information can be found at: www.noxxon.com
https://www.linkedin.com/company/noxxon-pharma-ag

Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

30/09/2017
29/09/2017

Initial data supports penetration of NOX-A12 into tumor tissue and previously established safety profile of NOX-A12 monotherapy in colorectal and pancreatic cancer patients

Berlin, Germany, September 28, 2017 – NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), provided today an update on the ongoing Phase 1/2 combination trial with NOXXON’s lead cancer compound, NOX-A12 and Merck & Co./MSD’s Keytruda® (pembrolizumab) in pancreatic and colorectal cancer patients.
The trial has enrolled 10 patients and therefore has successfully reached the halfway mark of the overall enrollment. The trial remains on schedule to deliver top-line biopsy analysis following NOX-A12 monotherapy and top-line response rates for all 20 patients to NOX-A12 in combination with Keytruda® in the second and fourth quarters of 2018 respectively.
Based on initial review of the two-week NOX-A12 monotherapy portion of the open-label study, NOX-A12’s safety and tolerability continue to be in line with previously reported and published data in that patients exhibit no major drug-related adverse effects. In addition, the currently available data from the first four enrolled patients suggest that NOX-A12 is able to penetrate into tumor tissue where it binds and neutralizes its target in both colorectal and pancreatic cancer patients. This analysis is based on levels of CXCL12 (C-X-C Chemokine Ligand 12), NOX-A12’s target, and other biomarkers measured in tumor biopsies.
“We are encouraged by the positive feedback we are receiving from clinicians and want to recognize their ongoing support and commitment to the study,” said Aram Mangasarian, CEO of NOXXON. “We remain focused on meeting the trial timelines, which should enable us to deliver top-line data for both parts of the study in 2018.”
The primary purpose of part 1 of the trial is to confirm that treatment with NOX-A12 can modulate the tumor microenvironment including the type, number and/or distribution of immune cells, such as cytotoxic T cells as well as chemokine and cytokine signatures in the tumor tissue. All patients completing part 1 move to part 2, in which they receive NOX-A12 in combination with Keytruda®. Part 2 is designed to explore the safety, tolerability and efficacy of NOX-A12 in combination with Keytruda®.

For more information, please contact:
NOXXON Pharma N.V.
Aram Mangasarian, Ph.D., Chief Executive Officer
Tel. +49 (0) 30 726 247 0
amangasarian@noxxon.com

MC Services AG
Raimund Gabriel, Managing Partner
Tel. +49 (0) 89 210228 0
noxxon@mc-services.eu
MacDougall Biomedical
Gretchen Schweitzer or Stephanie May
Tel. +49 (0) 89 2424 3494 or +49 (0) 172 861 8540
gschweitzer@macbiocom.com

NewCap
Florent Alba
Tel. +33 (0) 1 44 71 98 55
falba@newcap.fr

About NOX-A12
NOX-A12 (olaptesed pegol) is designed to fight tumors by modulating the tumor microenvironment. NOX-A12 targets and disrupts the signaling of a key chemokine (signaling) protein, CXCL12 (C-X-C Chemokine Ligand 12), which acts as a sign-post for migrating tumor and immune cells and a communication bridge between tumor cells and their environment. CXCL12 has been implicated in promoting tumor proliferation, new blood vessel formation and metastasis and reduction of tumor apoptosis (cell death). NOX-A12 has received orphan drug designation for glioblastoma in the United States and glioma in Europe.

About NOXXON
NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 will deliver top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018. Further information can be found at: www.noxxon.com
https://www.linkedin.com/company/noxxon-pharma-ag

Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

27/09/2017

Paris, France – September 27th, 2017 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Henrijette Richter as Managing Partner. She joins Antoine Papiernik, Denis Lucquin, Graziano Seghezzi and Monique Saulnier in the company’s Managing Partnership. With a 14 years’ experience in venture capital, Henrijette brings her extensive industry experience and strong international network to Sofinnova Partners’ leadership.

Henrijette joined Sofinnova Partners in October 2014, after seven years at Novo Holdings A/S (the holding company in the Novo Group) where she co-founded Novo Seeds. Prior to that, she worked at Sunstone Capital and was part of the founding team when the fund spun out of The Danish Growth Foundation. Henrijette is a scientist by training, she holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen, and did her postdoctoral fellowship at MIT Center for Cancer Research, Cambridge, MA.

Since 2014, Henrijette has lead key investments such as in Asceneuron, a biotech company specialized in neurodegenerative diseases headquartered in Switzerland where she also serves on the Board of Directors. Henrijette also seeded and invested in Delinia, a US-based company specialized in the treatment of auto-immune disorders that was sold to Celgene Corporation in January 2017 for a total value of up to $775 M.

Henrijette Richter says: « I am honored by this new role and excited to take a more active role in Sofinnova Partners’ growth strategy to reinforce its global leadership in Life Sciences. I have the foremost respect for the team, its values, the culture of diversity, and the entrepreneur-oriented spirit it has been fostering worldwide for more than forty years ».

Antoine Papiernik, Chairman of Sofinnova Partners, adds: « Henrijette stands out for her investment track record and has demonstrated impressive team leading skills. She is a great addition to our team, and we are extremely pleased to welcome her to the Managing Partnership as Sofinnova Partners is entering a new phase of its development ».
Press contact for SOFINNOVA PARTNERS
Anne REIN
Tel: +33 6 03 35 92 05
@: anne.rein@strategiesimage.com

19/09/2017

• The Company’s Antha operating system brings end-to-end digitization to biotechnology, replacing current artisanal methods of development
• Speaking from the World Economic Forum, Sustainable Development Impact Summit, CEO Tim Fell stresses the need to make biology a true engineering discipline
• Funding to support strategic partnership initiatives and extensively scale sales and marketing

LONDON & NEW YORK, 19 September 2017 – Synthace Ltd., the technology company behind the Antha operating system for biology today announced that it has raised £7.3m ($9.6m) in Series A funding.

White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital participated in the round alongside existing shareholders that included Sofinnova Partners, SOSV and Bioeconomy Capital.

Speaking from the World Economic Forum, Sustainable Development Impact Summit in New York, Synthace CEO Tim Fell said: “A sustainable future simply must include a better ability to engineer biology. Our need to heal, feed, fuel and manufacture for a growing population can be met by unlocking the near infinite power of biology but only by bringing software abstraction and more automation to biological R&D and manufacturing, and by enabling biologists to build atop their collective work. That is what the Antha platform does, and why we are so passionate about realizing its potential.”

Synthace will use the investment to expand the rapidly growing eco-system of biologists, lab instrumentation manufacturers, reagent and consumable suppliers, bio-design and analysis software developers and cloud providers adopting Antha as the connecting platform for biotechnology. This is key to enabling interoperability in hardware, working practices, and data in the life sciences, and something taken for granted in many other industries.

Isabel Fox, Head of Venture at White Cloud Capital, commented: “Synthace is transforming the way biotechnology is developed and the $170bn global life science R&D budget spent. The traction the Company has achieved with pharmaceutical, agritech and industrial biotechnology customers shows the cross-sector applicability of Antha. We are excited to support the company in bringing this technology to the immense market of any researcher or organisation developing products or services that incorporate biology.”

Hermann Hauser, Co-Founder and Partner, Amadeus Capital Partners, said: “Biotechnology has mass application, a true general purpose technology. Its development is challenging and Synthace is empowering biotechnologists to better understand and work with its complex nature. Amadeus is delighted to join this outstanding team on their important journey. Bioengineering and its implications for the future depend upon achieving step-change improvements in reproducibility, productivity and cost, all of which the Antha platform can deliver.”

“It is simply not good enough that it takes 13 years to develop a new crop trait or $2.6bn to bring a drug to market. The Pharma industry has a negative productivity curve stretching back 60 years, meanwhile the semiconductor industry has been marching to the beat of Moore’s law. Biotechnology desperately needs to move forward,” Fell concluded “and we know from other industries software driven design, development and manufacture is crucial to that transition”.

About Synthace
Based in London, Synthace is developing Antha, a language and software platform specifically for biology that lets researchers aim higher and achieve better results, faster. Antha is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment. In 2016, the World Economic Forum included Synthace in its selection of the world’s 30 most promising Technology Pioneers that are helping shape the Fourth Industrial Revolution – a technological revolution that will fundamentally alter the way we live, work and relate to one another. For more information, visit: www.synthace.com.

19/09/2017

Key Updates
• ProQR’s drug candidate QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation from the FDA, representing the fifth program in the Company’s pipeline to receive ODD in the U.S.
• The Company will be presenting pre-clinical data for QR-313 at two European scientific conferences in Salzburg, Austria – EB2017 Research Conference and ESDR Meeting.
• DEB is a severe genetic skin disease with no disease modifying treatments currently available.
• QR-313 targets the most common mutations within DEB, which are mutations in exon 73 of the COL7A1 gene and is designed for topical administration.
• A first-in-human clinical trial of QR-313 will be initiated in 2018. Clinical data from the program will also be available in 2018.

LEIDEN, the Netherlands, September 19, 2017 – ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that investigational drug QR-313 for dystrophic epidermolysis bullosa (DEB) has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA). QR-313 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause in dystrophic epidermolysis bullosa (DEB) due to mutations in exon 73 of the COL7A1 gene. DEB is a rare genetic disease that can lead to severe blistering of the skin resulting in high treatment burden and poor quality of life for patients.

“We are pleased to have ODD designation in the U.S. for our QR-313 program targeting dystrophic epidermolysis bullosa,” said David M. Rodman, MD, Chief Development Strategy Officer of ProQR, “It highlights the unmet need in this devastating disease, for which we aim to make a meaningful difference. Our goal for this disease is to develop a pipeline of programs that can treat DEB mutations in a targeted manner and to actively advance the pipeline through development.”

Poster Presentations at Upcoming Scientific Conferences
The Company will present two posters (# 50 and 51) during the EB2017 – 5th World Conference of Epidermolysis Bullosa Research Conference from September 24-26, 2017 in Salzburg, Austria.
The same posters (# 181 and 194) will also be presented at the 47th Annual European Society for Dermatological Research (ESDR) Meeting on September 29, 2017 in Salzburg, Austria. Poster #181 is selected for a presentation (walk title: Genetics and Cell Based Therapy 2: Epidermolysis bullosa) on September 29 at 14.35-15.30 CET.
The posters are titled:
• Local delivery of an antisense oligonucleotide for recessive dystrophic epidermolysis bullosa.
• In vitro evaluation of QR-313; an antisense oligonucleotide designed to skip exon 73 from the COL7A1 mRNA.
About Orphan Drug Designation (ODD)
Orphan drugs are intended for the treatment, diagnosis or prevention of serious diseases that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug. FDA evaluates scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. FDA provides incentives for sponsors to develop products for rare diseases, including development program tax benefits and a waiver of the NDA application user fee, as well as market exclusivity for up to seven years in the U.S.

About QR-313
QR-313 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of dystrophic epidermolysis bullosa (DEB) due to mutations in exon 73 of the COL7A1 gene. Mutations in this exon can cause loss of functional collagen type VII (C7) protein. Absence of C7 results in the loss of anchoring fibrils that normally link the dermal and epidermal layers of the skin together. QR-313 is designed to exclude exon 73 from the mRNA (exon skipping) and produce a functional C7 protein, thereby restoring functionality of the anchoring fibrils.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. *Since 2012*

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding QR-313 and the clinical development and the therapeutic potential thereof, and statements regarding our pipeline of programs targeting DEB. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, including that we may not realize the intended benefits afforded by orphan drug designation for our QR-313 program targeting DEB, positive results observed in our prior and ongoing studies may not be replicated in later trials or guarantee approval of any product candidate by regulatory authorities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.:
Media Contact:
Sariette Witte
T: +31 6 2970 4513 (NL)
T: + 1 213 261 8891 (US)
pr@proqr.com

Investor Contact:
Bonnie Ortega
T: +1 858 245 3983
ir@proqr.com